Global Erythropoietin (EPO) Market 2016 - Amgen, Johnson & Johnson, Roche, Kyowa Hakko Kirin, 3SBIO

Erythropoietin, also known as EPO, hematopoietin, or hemopoietin, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine (protein signaling molecule) for erythrocyte (red blood cell) precursors in the bone marrow. Human EPO has a molecular weight of 34 kDa.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

Download sample report at http://www.fiormarkets.com/report-detail/19781/request-sample

Exogenous erythropoietin can be provided to people whose kidneys cannot make enough. Recombinant human erythropoietin (rhEPO) is produced by recombinant DNA technology in cell culture. Several different pharmaceutical agents are available with a variety of glycosylation patterns and are collectively called erythropoiesis-stimulating agents (ESA). Major examples are epoetin alfa and epoetin beta. The specific details for labeled use vary between the package inserts, but ESAs have been used in the treatment of anemia in chronic kidney disease, anemia in myelodysplasia, and in anemia from cancer chemotherapy. Boxed warnings include a risk of death, myocardial infarction, stroke, venous thromboembolism, and tumor recurrence. rhEPO has been used illicitly as a performance-enhancing drug; it can often be detected in blood, due to slight differences from the endogenous protein, for example, in features of posttranslational modification.

This report provides detailed analysis of worldwide markets for Erythropoietin (EPO) from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Erythropoietin (EPO) market and further lays out an analysis of the factors influencing the supply/demand for Erythropoietin (EPO), and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

Access full report at http://www.fiormarkets.com/report/global-erythropoietin-epo-market-outlook-2016-2021-19781.html

Global Erythropoietin (EPO) Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Erythropoietin (EPO) market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Erythropoietin (EPO) market are Amgen (USA), Johnson & Johnson (USA), Roche (Switzerland), Kyowa Hakko Kirin (Japan), 3SBIO (China), among others.

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Erythropoietin (EPO) industry has been provided.

Fior Markets is a leading market intelligence company that sells reports of top publishers in the technology industry.

Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Fior Markets also specializes in analyzing hi-tech systems and current processing systems in its expertise.

Contact Us
Mark Stone
Sales Manager
Phone: (201) 465-4211
Email: sales@fiormarkets.com

This release was published on openPR.